Back

Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Congestion, SGLT2 inhibitors and novel therapies Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Anil Sahin

Canakkale 18 March University, Canakkale (Turkiye)

4 More presentations in this session

Presentation thumbnail
Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?
Professor E. Kelepouris (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Introduction and optimization of the guideline-directed medical therapy in patients hospitalized for acute heart failure (OPTICARD)
Doctor G. Baudry (Nancy, FR)
Abstract Slides Video
Presentation thumbnail
The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure
Doctor I. Lala (Timisoara, RO)
Abstract Slides Video

Access the full session

Session thumbnail
Congestion, SGLT2 inhibitors and novel therapies

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease
thumbnail
Congress Presentation
Comparing treatment strategies for heart failure: a real-world analysis of adding ARNI or SGLT2i to older GDMT
thumbnail
Congress Presentation
Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources